Form 4: TherapeuticsMD Director Collins Increases Stake with $1.734 Purchase

Director Cooper C. Collins of TherapeuticsMD, Inc. (TXMD) acquired 4,094 shares of common stock at a weighted average price of $1.734 on August 22, 2024.

Summary

• On August 22, 2024, Cooper C. Collins, a director of TherapeuticsMD, Inc. (TXMD), purchased 4,094 shares of the company's common stock.
• The shares were acquired at a weighted average price of $1.734 per share.
• The purchase price ranged from $1.69 to $1.75 per share.
• Following the transaction, Collins directly owns 52,016 shares of TherapeuticsMD.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the transaction is relatively small and may not be highly significant.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and potential future performance.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

TherapeuticsMD, TXMD, director, insider trading, stock purchase, Cooper C. Collins, Form 4